Akari Therapeutics Plc 8-K Filings

Akari Therapeutics reported results of its June 30, 2026 Annual General Meeting. Shareholders approved the 2025 financial statements, most director re-elections, and the appointment and remuneration of BDO USA, P.C. and HaysMac LLP as auditors.

Shareholders also approved several equity-related items, including issuances under an ELOC Purchase Agreement, warrants and placement agent American Depositary Shares tied to May 20, 2026 securities and placement agent agreements, and a potential private placement that could result in a change of control. They authorized directors to allot shares up to an aggregate nominal amount of USD 20,000 through June 30, 2031 and passed a related special resolution allowing certain cash issuances without pre-emption rights.

Director James Neal was not re-elected and left the Board at the meeting’s conclusion. Following this, Dr. Ray Prudo joined the Audit Committee and Robert Bazemore became Chair of the Compensation Committee.

Akari Therapeutics, Plc reported an amendment to its securities purchase agreement with certain investors for a previously announced private placement of American Depository Shares (ADSs) and related warrants. The amendment combines the originally planned second and third funding closings into a single consolidated closing.

The private placement covers 1,470,588 unregistered ADSs, or prefunded warrants to purchase ADSs, each ADS representing 80,000 ordinary shares, together with Series H, Series I and Series J warrants. On the June 26, 2026 combined closing date, Akari issued the remaining 980,395 ADSs or prefunded warrants due under the agreement.

Delivery of the Series H, Series I and Series J warrants to investors remains contingent on receiving shareholder approval at Akari’s annual general meeting scheduled for June 30, 2026. Other than changing the closing schedule, the amendment leaves all other purchase agreement terms unchanged.

Akari Therapeutics entered into a securities purchase agreement for a private placement of 1,470,588 American Depositary Share units. Each unit consists of one ADS or a pre-funded warrant plus Series H, I and J warrants, at an ADS unit purchase price of $3.74 or $3.739 for pre-funded units.

The transaction is expected to generate approximately $5.5 million in gross proceeds before about $125,000 of placement agent fees, with closings anticipated around May 27, 2026, June 15, 2026 and July 15, 2026. Net proceeds are earmarked for working capital and general corporate purposes.

Investors receive warrants exercisable at $3.74 per ADS, and the placement agent receives a 2% cash fee plus 117,647 ADSs, both subject to shareholder approval. Akari plans to file a registration statement to register the resale of the shares and warrant shares purchased in this offering.

Akari Therapeutics, Plc is changing the ratio of its American Depositary Shares to ordinary shares from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares. This ratio change produces a one-for-forty reverse split of the issued and outstanding ADSs only.

The ratio change is expected to be effective on or about March 31, 2026 and is intended to help the company maintain compliance with Nasdaq’s minimum bid price requirement. The company’s underlying ordinary shares are unchanged, and the ADSs will continue to trade on the Nasdaq Capital Market under the symbol AKTX.

No fractional new ADSs will be issued. Instead, fractional entitlements will be aggregated and sold, and net cash proceeds after fees, taxes and expenses will be distributed to affected ADS holders by the depositary bank, Deutsche Bank.

Akari Therapeutics, Plc reported results of a special general meeting where shareholders approved several warrant-related resolutions tied to prior financings and note exchanges. The meeting was held on March 2, 2026, with 91,567,009,533 ordinary shares entitled to vote, and all proposals passed.

Shareholders approved, for Nasdaq Listing Rule 5635(c) and 5635(d) purposes, the exercisability and related issuances for Series G Warrants and Placement Agent Warrants covering up to 10,043,774 and 504,300 American Depositary Shares, respectively. They also approved the exercisability of various Pre-Funded, Series G, and Note Exchange Warrants covering multiple blocks of ADSs issued in December 2025 transactions.

Akari Therapeutics reported a set of concurrent equity-related transactions expected to reshape its financing. The company agreed to a registered direct offering and concurrent private placements of American Depositary Shares (ADSs) and warrants, with aggregate gross cash proceeds expected to be approximately $5 million. Investors will purchase 10,043,774 ADSs with accompanying Series G warrants, while certain directors and officers will purchase pre-funded warrants for 2,563,713 ADSs plus matching Series G warrants.

Separately, Akari entered into note exchange agreements to cancel approximately $4 million in principal of its 2026 unsecured promissory notes in return for new pre-funded and note exchange warrants, after which those notes will be retired at closing. The Series G and note exchange warrants have an exercise price of $0.3883 per ADS and generally become exercisable after shareholder approval, subject to 4.99%–9.99% beneficial ownership limits. The company plans to use net proceeds for continued research and development, working capital and general corporate purposes.

Akari Therapeutics, Plc reported that shareholders approved all proposals at a special general meeting held on December 15, 2025. A total of 71,479,461,523 ordinary shares were entitled to vote, and a quorum was present.

Shareholders backed the exercisability of certain warrants and the issuance of the ordinary shares underlying those warrants issued in an October 14, 2025 offering. They also approved a subdivision and re-designation of each ordinary share of USD 0.0001 into one Ordinary Share of USD 0.000000005 and 19,999 deferred shares of USD 0.000000005, new authority for directors to allot shares and grant rights up to an aggregate nominal amount of USD 3,000 until June 30, 2030, a share buyback contract for all Deferred Shares lasting until December 15, 2026, a five-year disapplication of statutory pre-emption rights for certain cash issuances, and the adoption of new articles of association.

Akari Therapeutics, Plc reported that it has prepared a new investor presentation dated December 8, 2025. Company officers and representatives intend to use this presentation at conferences and meetings to explain Akari’s business and prospects to current and potential investors.

The materials are provided as an exhibit to this report and are classified as “furnished” rather than “filed,” meaning they are not subject to certain liability provisions of the U.S. securities laws and are not automatically incorporated into other company filings.

Akari Therapeutics has received a notice from Nasdaq that its American Depositary Shares (ADSs) no longer meet the exchange’s minimum bid price requirement of $1.00 per share. The ADSs closed below this level for 30 consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5550(a)(2). The notice does not immediately affect trading, and the ADSs will continue to trade on the Nasdaq Capital Market under the symbol AKTX.

Akari has 180 calendar days, until May 25, 2026, to regain compliance by having its ADSs close at or above $1.00 for at least 10 consecutive business days. If it still does not meet the requirement, it may qualify for an additional 180-day period if it satisfies other Nasdaq listing standards, or it could ultimately face delisting, with the right to appeal. The company plans to monitor its share price and may consider options such as changing the ADS ratio to restore compliance.

Akari Therapeutics (AKTX) appointed Kameel Farag as interim CFO, effective October 22, 2025, succeeding prior CFO Torsten Hombeck. Farag brings senior finance experience from Aspen Neuroscience, Ionis, and Amgen, and serves on the Biovie board.

The company entered a Consulting Agreement with Farag and KDF Ventures LLC. Through the end of 2025, compensation is $18,000 per month in cash plus $12,000 in RSUs, vesting monthly. From January 1, 2026 to February 15, 2026, fees increase to $27,000 cash plus $13,000 in RSUs, vesting monthly. The agreement runs to February 16, 2026 and can be extended month‑to‑month at the company’s discretion. In connection with certain capital raises, KDF Ventures may receive additional cash and RSU compensation based on a percentage of total gross proceeds, subject to maximum limits and timing conditions.

Akari Therapeutics entered a registered direct offering of 3,125,000 ADSs at $0.80 per ADS, for expected $2.5 million in aggregate gross proceeds, subject to customary closing conditions. The ADS sale is a takedown from Akari’s effective Form F-3 shelf.

Concurrently, the company issued Series E and Series F warrants in a private placement, each exercisable for up to 3,125,000 ADSs at an exercise price of $0.98 per ADS. Both series become exercisable on the effective date of shareholder approval; Series E carries a five-year term and Series F a thirty‑month term. Akari will file a resale registration for the warrant shares within 30 days of closing and will call a shareholder meeting within 60 days to seek approval, then every 40 days until obtained or the warrants expire.

Ladenburg Thalmann is placement agent, entitled to a 7.2% fee, 0.5% management fee, up to $75,000 expense allowance, and Placement Agent Warrants to purchase 125,000 ADSs at $1.00 per ADS (five‑year term). The purchase agreement includes a 30‑day issuance/registration standstill and a one‑year prohibition on variable rate transactions, in each case with customary exceptions.

Akari Therapeutics (AKTX) furnished an 8-K announcing a $2.5 million registered direct offering. The company disclosed, under Item 7.01 (Regulation FD), that it issued a press release titled “Akari Therapeutics Announces $2.5 Million Registered Direct Offering.” The press release is included as an exhibit and the furnished information is not deemed filed under the Exchange Act.

Akari’s American Depositary Shares, each representing 2,000 ordinary shares, trade on Nasdaq under the symbol AKTX. The filing lists the date of the earliest event as October 15, 2025.

Akari Therapeutics, Plc reports that it has completed its previously disclosed August 2025 unsecured promissory notes financing. The company had agreed to sell notes with a 20% original issue discount for an aggregate purchase price of $3 million, resulting in a total principal amount of approximately $3.8 million.

On September 26, 2025, Akari closed the final tranche of this private placement, issuing $312,500 in aggregate principal amount of August 2025 Notes for a purchase price of $250,000. After this closing, the full approximate $3.8 million principal amount of August 2025 Notes has been issued to investors.

Akari Therapeutics reported several financing changes and new preclinical data. The company amended its April 2023 convertible notes and warrants assumed in its merger with Peak Bio. The maturity of $0.7 million principal of notes was extended to August 31, 2026 and the conversion price was reduced to $0.81 per ADS. The related warrants were extended to August 31, 2030, with 342,420 ADSs now issuable at an exercise price of $0.81 per ADS, and holders will receive about $81,700 of accrued interest.

Akari also closed a second tranche of its August 2025 notes offering, issuing $625,000 principal for $500,000 in proceeds, bringing total August 2025 notes issued to $3.5 million principal. In connection with this, Series A warrants to purchase 4,891,272 ADSs had their expiration extended to April 25, 2030. Separately, Akari described preclinical results for its PH1 antibody-drug conjugate payload showing AR-V7 suppression and combination activity with existing androgen receptor pathway inhibitors in prostate cancer models.

Akari Therapeutics entered into an Ordinary Share Purchase Agreement with White Lion Capital, giving Akari the right, but not the obligation, to sell up to $25,000,000 of newly issued ordinary shares, which may be exchanged for ADSs. Akari can draw on this equity line over a period ending on the earlier of the full $25,000,000 being purchased or August 29, 2028, once a resale registration statement is declared effective. Pricing is based on several notice types, including rapid purchase options tied to the lowest traded ADS prices and VWAP-based purchases at 97%–98% of VWAP.

The agreement caps issuances at 13,039,369,358 ordinary shares, equal to 19.99% of Akari’s outstanding ordinary shares as of the execution date, and includes a Beneficial Ownership Limitation initially set at 4.99%, which the purchaser may increase to 9.99% with notice. Akari will pay fees including a $15,000 document preparation fee and additional cash commitment fees, and may issue commitment shares equivalent to $75,000 if minimum drawdown conditions are not met. Concurrently, Akari agreed to file a Form S-1 to register the resale of the related securities. The company also disclosed that its CFO, Torsten Hombeck, will resign effective October 10, 2025, and then serve as a consultant through at least November 30, 2025 for transition, citing personal reasons.

Akari Therapeutics plc disclosed that its Chairman, Dr. Hoyoung Huh, purchased a Note with a $1,250,000 principal amount for a purchase price of $1,000,000. The purchase was satisfied with $162,567 in cash and by cancelling $837,433 of outstanding principal and accrued interest under a senior secured promissory note previously issued to him by the companys subsidiary, Peak Bio Inc. The company and Dr. Huh executed a Loan Cancellation and Exchange Agreement on August 7, 2025, to effect the cancellation; the full agreement is filed as Exhibit 10.1 to the Form 8-K.

Akari Therapeutics, Plc filed a current report to let investors know it has released an updated corporate investor presentation. The company states that this updated presentation, attached as Exhibit 99.1, will be used by its representatives in various meetings with investors and other stakeholders from time to time.

The information in this presentation is furnished under a Regulation FD disclosure, meaning it is intended to provide broad, fair disclosure but is not treated as filed for liability purposes under the Exchange Act. Akari also notes that the materials will only be incorporated into other securities law filings if specifically referenced in those future documents.